Investing.com - Janux Therapeutics (NASDAQ: JANX) reported second quarter EPS of $-0.11, $0.20 better than the analyst estimate of $-0.31. Revenue for the quarter came in at $8.89M versus the consensus estimate of $772K.
Janux Therapeutics's stock price closed at $35.29. It is down -27.86% in the last 3 months and up 178.31% in the last 12 months.
Janux Therapeutics saw 2 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Janux Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Janux Therapeutics's Financial Health score is "fair performance".
Check out Janux Therapeutics's recent earnings performance, and Janux Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar